Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
about
BMI1: A Biomarker of Hematologic MalignanciesIn vitro comparative models for canine and human breast cancersThe effects of microRNA on the absorption, distribution, metabolism and excretion of drugsSmall non-coding RNAs govern mammary gland tumorigenesisDecoding the usefulness of non-coding RNAs as breast cancer markersMiRNAs and miRNA Polymorphisms Modify Drug ResponseMicroRNAs targeting prostate cancer stem cellsmiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2Increased circulating microRNA-155 as a potential biomarker for breast cancer screening: a meta-analysis.MicroRNAs in pathogenesis of breast cancer: Implications in diagnosis and treatment.Apoptotic death of cancer stem cells for cancer therapy.Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC.Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia.miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells.Midbrain dopamine neurons in Parkinson's disease exhibit a dysregulated miRNA and target-gene networkEpigenetic Regulation of miRNAs and Breast Cancer Stem Cells.BMI-1, a promising therapeutic target for human cancer.miR-128 modulates hepatocellular carcinoma by inhibition of ITGA2 and ITGA5 expression.Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cellsMicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective TherapyRole of microRNAs in breast cancer.The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2).Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.Negative regulation of Bmi-1 by AMPK and implication in cancer progression.MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1.The role of microRNAs in breast cancer stem cells.Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.Identification of microRNAs dysregulated in cellular senescence driven by endogenous genotoxic stress.Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis.MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells.Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.Multidrug-resistant breast cancer: current perspectives.The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinomaVEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells.Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancerRole of microRNAs in the regulation of drug metabolizing and transporting genes and the response to environmental toxicants.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications.miRNAs as mediators of drug resistance.
P2860
Q26750676-0DB36363-7A38-48D0-AAEF-29EA1D09275AQ26752714-E2E12718-9989-4A42-8BC2-5BBFE7A386BEQ26822987-B04BA9C8-531F-47BD-812C-B43AA2FA27D3Q27007057-2A498B00-7DEB-4CA7-B856-F01A5CDD12B3Q28069370-D8600A10-DA00-45AF-88A8-567D6E563B2BQ28079075-35F9C18A-00A0-4DE7-9B0B-B769908CF7A6Q28081039-215E7C68-00FA-45D3-9099-E462A249C3A8Q28606716-2B9B130D-C22F-4B7B-85D6-7A00A09F238DQ31161472-01900C41-8F49-44CD-AB3D-EBF8E6C3B958Q33585094-6580568C-D90D-4FA2-80D0-1B02CFB68BC1Q33755766-7499E957-03DA-40AC-93CA-BE99BFC5CB9EQ33827178-65540A1A-A8B0-4015-9FDC-4FB58335F763Q33888935-B2C57479-7E55-4B4C-BDAA-BD0B0D73D4A5Q35181216-CFE07DED-28DF-4B4C-B802-41D7C249F7F1Q35369612-DC2D3CDE-86DE-462E-8257-8C2C5584430EQ35654904-074BE91B-54F3-424A-B55A-5115292E4BC9Q35673753-7DC795E9-DF5E-4A08-B7E1-9862845A5DD1Q35870390-48FD7F49-B4FD-4060-9CFF-44CCDCE27C38Q36225840-115D2964-1137-4185-8BF8-6041B0BD5970Q36485168-88C41DDF-33A1-45A9-A8C7-060361E66BCBQ36618667-08976D0F-098C-432C-A001-78AAF6CF1ED3Q36677690-468E6C9D-4782-483D-8BF8-18B37449A113Q36779495-01906B39-597B-4CCB-A10A-3DDE1009590DQ36835708-A7E297F8-886A-4691-9926-B1FEBBF9BFD4Q36905874-7C917029-2DAE-4521-859B-B2BE60BB2B71Q37045562-4FE7D559-1371-44C6-A4F3-16A426F1121AQ37092013-A4A3FAD2-8235-406E-886B-2FB50762BB68Q37193085-4215A713-76C5-4D5D-A897-A149D894BD38Q37298895-CA3BBF48-276A-464F-86F5-62CBF8B6DC39Q37332728-FC4FFD85-0439-46A0-9442-D568E731E3E6Q37348877-3E432988-6C73-4B9A-98CE-5F8078B9197BQ37569328-D87F8F64-89B5-4EA0-957C-05DF71122DE8Q37593383-28654F46-658C-42F6-9B54-174C82BEC193Q37644821-8ED3D1FB-943E-4B76-8DF1-C2CFD04D0111Q37672753-258C741C-AB88-42F1-AB5D-CD0E3CC8692DQ37689064-EAF17545-A24C-44A2-9C9A-596BDAFFD7E5Q37995667-620DF39B-88E3-4D60-9E4F-C9F9108A7624Q38023238-0D4B2310-5D7A-4719-9F35-865E2CA602C4Q38036917-AD2C54EE-E801-49F6-8ECE-E87F48224F93Q38037620-DD1310B3-7646-4478-90E3-C2FA8144B725
P2860
Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Reduced miR-128 in breast tumo ...... esistance via Bmi-1 and ABCC5.
@en
type
label
Reduced miR-128 in breast tumo ...... esistance via Bmi-1 and ABCC5.
@en
prefLabel
Reduced miR-128 in breast tumo ...... esistance via Bmi-1 and ABCC5.
@en
P2093
P1476
Reduced miR-128 in breast tumo ...... esistance via Bmi-1 and ABCC5.
@en
P2093
Chang Gong
Erwei Song
Fengyan Yu
Jianing Chen
Yinghua Zhu
P304
P356
10.1158/1078-0432.CCR-11-0071
P407
P577
2011-09-27T00:00:00Z